| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
The primary targets of 2-Thiophenecarboxaldehyde are not well-defined as a specific receptor or enzyme target, as it is primarily used as a synthetic building block. However, it serves as a precursor for the synthesis of various pharmacologically active compounds, including the anthelmintic drug pyrantel and the antihypertensive drugs eprosartan and azosemide. As an endogenous metabolite, it may interact with various metabolic pathways. These characteristics make it relevant for medicinal chemistry and drug synthesis research.
|
|---|---|
| ln Vitro |
In vitro, 2-Thiophenecarboxaldehyde is used primarily as a chemical intermediate in organic synthesis rather than as a pharmacologically active compound. It is employed in the synthesis of β-aryl-β-amino acids, urea derivatives, and as an arylation reagent. The compound’s reactivity as an aldehyde makes it a versatile building block for constructing complex molecules in research and industrial chemistry. It is also used in the synthesis of conducting polymers due to its unique Hammett electronic character. These in vitro applications support its use in synthetic chemistry and materials science.
|
| ln Vivo |
In vivo, 2-Thiophenecarboxaldehyde is an endogenous metabolite found naturally in various organisms. It has been reported in plants such as Capparis spinosa and Coffea arabica, and in the marine organism Sergia lucens. However, its specific in vivo functions and metabolic roles have not been extensively characterized. The compound is not used as a therapeutic agent itself, but its derivatives, including drugs such as eprosartan and pyrantel, have significant clinical applications.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (cell-free) assays for 2-Thiophenecarboxaldehyde are not typically conducted, as it is not a conventional enzyme inhibitor or receptor ligand. However, its aldehyde reactivity can be studied in various chemical assays. The compound can be used as a substrate for aldehyde dehydrogenase or other oxidoreductases to study enzyme kinetics. Enzyme activity is measured spectrophotometrically by monitoring NADH or NADPH production. All assays include appropriate controls and reference compounds.
|
| Cell Assay |
In vitro cell-based assays for 2-Thiophenecarboxaldehyde are limited, as the compound is primarily used as a synthetic intermediate. Cytotoxicity studies may be performed to assess safety. Cells are treated with compound concentrations ranging from 0.1-1000 μM for 24-72 hours. Cell viability is assessed using MTT assays. The compound’s effects on cellular metabolism may be evaluated. All experiments include vehicle controls.
|
| Animal Protocol |
In vivo animal studies with 2-Thiophenecarboxaldehyde are limited, as the compound is primarily a synthetic intermediate rather than a therapeutic agent. However, its derivatives, such as the antihypertensive drug eprosartan and the anthelmintic drug pyrantel, have been extensively studied in animal models. These studies evaluate efficacy, pharmacokinetics, and safety of the drug products. Each study includes appropriate controls and follows standard protocols for the specific therapeutic indication.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2-Thiophenecarboxaldehyde have not been extensively characterized, as it is primarily used as a synthetic intermediate. As a small, lipophilic molecule (logP 1.02), it is expected to have good oral bioavailability and tissue distribution. The compound is soluble in DMSO at approximately 100 mg/mL. Metabolism likely occurs through oxidation of the aldehyde group to the corresponding carboxylic acid, followed by conjugation and renal excretion. Detailed PK parameters require further investigation.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2-Thiophenecarboxaldehyde are limited, as it is primarily used as a synthetic intermediate. The compound may cause skin and eye irritation. Appropriate safety precautions should be taken during handling, including use of personal protective equipment and adequate ventilation. Comprehensive toxicological studies have not been conducted for this compound alone.
|
| Additional Infomation |
Formylthiophene is an aldehyde, a compound in which the thiophene ring is replaced by a formyl group at the 2-position. It is a metabolite, belonging to the thiophene class of compounds, and is also an aldehyde. It has been reported that thiophene-2-carboxaldehyde is present in capparis spinosa, Arabica coffee (Coffea arabica), and jujube (Sergia lucens), and relevant data already exist.
2-Thiophenecarboxaldehyde is an aromatic heterocyclic aldehyde and endogenous metabolite used primarily as a synthetic building block in medicinal chemistry and materials science. It is a precursor for the synthesis of drugs such as eprosartan, azosemide, and pyrantel. The compound is also used in the synthesis of conducting polymers. It is not approved for clinical therapeutic use and is intended for research and industrial applications only. |
| Molecular Formula |
C₅H₄OS
|
|---|---|
| Molecular Weight |
112.15
|
| Exact Mass |
111.998
|
| CAS # |
98-03-3
|
| PubChem CID |
7364
|
| Appearance |
Light yellow to brown liquid
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
198.0±13.0 °C at 760 mmHg
|
| Melting Point |
<10ºC
|
| Flash Point |
77.8±0.0 °C
|
| Vapour Pressure |
0.4±0.4 mmHg at 25°C
|
| Index of Refraction |
1.610
|
| LogP |
1.02
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
7
|
| Complexity |
72.5
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=CC1=CC=CS1
|
| InChi Key |
CNUDBTRUORMMPA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H4OS/c6-4-5-2-1-3-7-5/h1-4H
|
| Chemical Name |
thiophene-2-carbaldehyde
|
| Synonyms |
2Thiophenecarboxaldehyde; 2 Thiophenecarboxaldehyde
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~891.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (22.29 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (22.29 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (22.29 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.9166 mL | 44.5831 mL | 89.1663 mL | |
| 5 mM | 1.7833 mL | 8.9166 mL | 17.8333 mL | |
| 10 mM | 0.8917 mL | 4.4583 mL | 8.9166 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
